Drugs / CD19CAR-28-zeta T cells
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT00586391 | Feb 2009 → Jul 2014 overdue | B-cell chronic lymphocytic leukemia | Baylor College of Medicine | Active not recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CD19CAR-28-zeta T cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00586391 ↗ |
| Action | Deplete | “T cells, also called T lymphocytes, are special infection-fighting blood cells that can kill other cells including tumor cells.” NCT00586391 ↗ |
| Modality | Cell therapy | “This research study is a gene transfer study using special immune cells.” NCT00586391 ↗ |
| Route | Intravenous | “Patients will be given an injection of cells into the vein through an IV at the assigned dose.” NCT00586391 ↗ |